On-premise analysis appliances provide lower cost analysis, greater control over patient data and large, data storage cost-savings.
Supports Illumina, BGI, Oxford Nanopore Technology and PacBio sequencing.
Two variant callers; higher quality, proprietary, Novos variant caller, as well as standard Broad Institute (GATK) variant caller; SNPs, indels, structural variants, copy number variants and mitochondrial. Identifies more true-positives and returns fewer false-positive variants.
Reduces days of secondary analysis and variant interpretation into minutes through automation and AI technology.
Built to scale, from analyzing a few exomes up to thousands of whole genomes. Your OmniTier infrastructure can scale up as your analytics volumes grow.
End-to-end, easy to use, built-in analysis workflows. Designed for researchers, clinicians and bioinformaticians, rather than IT and software specialists.
Analysis tools that all researchers, clinicians and bioinformaticians can agree on.
Genomenon and OmniTier Partner to Bring Mastermind’s Evidence Sources to CompStor Insight
Ann Arbor, Michigan – Genomenon®, Inc., an AI-driven genomics company, announced a partnership with OmniTier, which includes integration of the Mastermind® Genomic Search Engine into their on-premises based CompStor Insight® genomics analysis platform.
OmniTier customers keep control and retain ownership of their genomics data
(BAY AREA, CA, USA November 9th, 2021) In response to requirements from some competing human genomics analysis providers to allow them certain usage rights over the customer’s data, OmniTier announces that customers using its secondary analysis and variant interpretation appliances, CompStor Novos® and CompStor Insight® keep full control and ownership of all their data.
Mitochondrial DNA analysis is added to OmniTier’s CompStor® family of genomics secondary and tertiary analysis appliances
(SAN JOSE, CA, USA – March 1st, 2021) OmniTier announced today that its CompStor® family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances. Accurate identification of the mitochondrial genome are key requirements for researchers and clinicians seeking to improve their understanding of mitochondrial dysfunction.